| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 16.83▼ | 16.70▲ | 16.74▲ | 16.22▲ | 15.25▲ |
| MA10 | 16.73▲ | 16.71▲ | 16.71▲ | 15.91▲ | 12.66▲ |
| MA20 | 16.73▲ | 16.64▲ | 16.58▲ | 15.73▲ | 11.23▲ |
| MA50 | 16.69▲ | 16.13▲ | 15.57▲ | 12.77▲ | N/A |
| MA100 | 16.58▲ | 15.59▲ | 15.74▲ | 11.08▲ | N/A |
| MA200 | 15.76▲ | 15.77▲ | 14.49▲ | 10.78▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.017▲ | -0.031▼ | -0.028▼ | -0.059▼ | 0.995▲ |
| RSI | 56.727▲ | 61.363▲ | 67.653▲ | 64.904▲ | 65.031▲ |
| STOCH | 90.397▲ | 71.411 | 81.121▲ | 64.524 | 83.038▲ |
| WILL %R | -15.000▲ | -11.538▲ | -8.054▲ | -7.365▲ | -2.644▲ |
| CCI | 71.748 | 120.307▲ | 109.027▲ | 113.774▲ | 124.490▲ |
|
Tuesday, August 12, 2025 04:16 AM
Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis ...
|
|
Monday, July 28, 2025 10:42 AM
Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s potential. Click for more on ZBIO stock.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 16.88 | 17.00 | 16.14 | 16.82 | 128,600 |
| 14/08/25 | 16.62 | 16.93 | 15.61 | 16.76 | 78,539 |
| 13/08/25 | 16.20 | 16.95 | 16.08 | 16.71 | 78,000 |
| 12/08/25 | 14.51 | 16.17 | 14.51 | 15.90 | 98,042 |
| 11/08/25 | 14.76 | 15.25 | 14.389 | 14.905 | 87,800 |
| 08/08/25 | 14.81 | 14.81 | 13.99 | 14.63 | 84,361 |
| 07/08/25 | 15.61 | 15.65 | 14.04 | 14.80 | 175,200 |
| 06/08/25 | 16.105 | 16.38 | 15.00 | 15.70 | 116,487 |
| 05/08/25 | 16.77 | 16.77 | 15.32 | 16.09 | 144,500 |
| 04/08/25 | 15.62 | 17.045 | 15.2001 | 16.81 | 166,231 |
|
|
||||
|
|
||||
|
|